论文部分内容阅读
目的:观察复方苦参注射液结合肝动脉介入治疗原发性肝癌的疗效。方法:选取我院收治的原发性肝癌患者共120例,随机分为观察组和对照组,两组均采用肝动脉介入治疗,而观察组加用复方苦参注射液。结果:治疗后观察组的中医症状明显比对照组患者低(P<0.05),而体力状况明显比对照组患者高(P<0.05);治疗后观察组患者的完全缓解率明显高于对照组(41.7%VS 11.7%,P<0.05),而无效率明显低于对照组(45.0%VS 76.7%,P<0.05);治疗后观察组的AST、ALT、TBIL水平明显低于对照组(P<0.05)。结论:采用复方苦参注射液结合肝动脉介入治疗原发性肝癌,用药安全、有效,能够改善患者的中医症状,缓解疼痛,改善肝功能,提高患者的生活质量。
Objective: To observe the curative effect of Compound Kushen Injection and Hepatic Artery Intervention on Primary Liver Cancer. Methods: A total of 120 primary hepatocellular carcinoma patients admitted to our hospital were randomly divided into observation group and control group. Both groups were treated with hepatic artery intervention, and compound Kushen injection was used in the observation group. Results: After treatment, the symptom of TCM in the observation group was significantly lower than that in the control group (P <0.05), while the physical condition was significantly higher than that in the control group (P <0.05). After treatment, the complete remission rate in the observation group was significantly higher than that in the control group (41.7% vs. 11.7%, P <0.05), while the inefficacy was significantly lower in the observation group than in the control group (45.0% vs 76.7%, P <0.05). The levels of AST, ALT and TBIL in the observation group were significantly lower than those in the control group <0.05). Conclusion: The compound Kushen injection and hepatic artery interventional treatment of primary liver cancer, safe and effective medication, can improve the symptoms of patients with traditional Chinese medicine, relieve pain, improve liver function and improve the quality of life of patients.